Von Hoff, MD, FACP, global principal investigator of the NAPOLI-1 study, Chief Scientific Officer for HonorHealth Analysis Institute and Physician-In-Chief and Distinguished Professor at TGen. The large, randomized medical trial that evaluated the new medication, the NAPOLI-1 , was sponsored by Merrimack Pharmaceuticals. It evaluated individuals enrolled at more than 100 sites in THE UNITED STATES, South America, Europe, Australia and Asia, including patients at HonorHealth Analysis Institute.It remains prematurily. To assess the influence of the additional radiotherapy on cardiovascular disease and second cancers. When we designed our trial, there was no plan to adjust the P value for multiple comparisons of secondary outcomes in the event that the primary outcome was not significant. Inferences on the noticed treatment results for secondary outcomes in our analysis could be less robust due to the issue of multiple testing.20 Axillary dissection occurred in 96 percent of patients in our trial.21 In the absence of a randomized trial evaluating the addition of regional nodal irradiation to whole-breast irradiation in individuals with positive results on sentinel-lymph-node biopsy without axillary dissection, we feel that it is reasonable to speculate that the outcomes of our study could be applicable to such individuals, because so many of the cancer-containing axillary nodes are removed.